GPR35 Agonist Compounds for Inflammatory Bowel Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GPR35 agonists exhibit weak activity and lack target specificity, hindering the understanding of GPR35 biology and the development of effective treatments for diseases associated with this receptor, particularly in inflammatory bowel disease and pain management.
Innovation Solution
Development of novel compounds with specific activity as GPR35 receptor agonists, represented by specific chemical formulas, which can be used to treat mast cell disorders, pain conditions, and inflammatory or allergic diseases in the gastrointestinal and lung systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current GPR35 agonists (such as zaprinast, pamoic acid, cromolyn, loop diuretic drugs, aspirin metabolites, quercetin, dicumarol, sulfasalazine, 5-aminosalicylic acid, tyrophstin, entacapone) are used, then GPR35 receptor activation is achieved, but the activity is weak and target specificity is lacking
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structures (molecular weight, logP, hydrogen bond donors/acceptors, aromatic rings) to optimize both potency and selectivity. The defined chemical space with specific parameter ranges enables the discovery of compounds with enhanced GPR35 activation while maintaining target specificity, directly resolving the contradiction between efficacy and specificity.
2Reliability
If current GPR35 agonists are used, then some biological activity is observed, but the activity is only partial and the compounds lack adequate pharmacological tractability for dissecting GPR35 pathways
Solution Approach 1:
The patent defines specific chemical parameter ranges (molecular weight 200-500, logP 2-5, hydrogen bond donors 0-3, aromatic rings 1-3) to systematically optimize compound properties. This structured approach enables the identification of agonists with sufficient potency and selectivity to serve as effective pharmacological tools for dissecting GPR35 signaling pathways, thereby improving both biological activity and pharmacological tractability.
3Adaptability or versatility
If putative endogenous ligand kynurenic acid is used, then species selectivity is observed (100 fold lower potency at human receptor compared to rat ortholog), but this complicates the understanding of true GPR35 biology
Solution Approach 1:
The patent creates synthetic analogs that replicate and refine the pharmacological properties of putative endogenous ligands. By designing compounds with optimized chemical parameters that overcome species selectivity issues and enhance potency, the patent provides improved pharmacological tools that more accurately reflect human GPR35 biology, thereby reducing information loss about the true ligand identity and receptor function.
Data Source
AI summary
The disclosures herein relate to novel compounds of formula (1):and salts and any tautomers thereof, wherein X, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR35 receptors.